2Huilan S, Zhen LG, Mathan MM, et al. Etiology of acute diarrhea among children in developing countries: a muhicentre study in five countries[J]. Bull World Health Organ 1991, 69:549-555.
8Yang HH, Wu CG, Xie GZ, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China [J]. Bull WHO 2001,79(7) :625- 631.
9Lanb MN, Lin FY, Bay PV, et al. Persistence of antibodies and efficacy against typhoid fever 28- 46 months following Vi conjugate vaccine(Vi-rEPA) in 2 to 5 years-old children[J].N Engl J Mod 2003, 349 : 1390-1391.
3Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med, 1983, 308: 681-685.
4Bell BP, Griffin PM, Lozano P, et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157 infections. Pediatrics, 1997, 100(1): E12.
6Fitzhenry RJ, Pickard DJ, Hartland EL, et al. Intimin type influences the site of human intestinal mucosal colonization by enterohaemorrhagic Escherichia coli O157:H7. Gut, 2002, 50(2): 180-185.
7Son WG, Graham TA, Gannon VPJ, et al. Immunological characterization of Escherichia coli O157:H7 intimin gamma1. Clin Diagn Lab Immunol, 2002, 9(1): 46-53.
8Dean NEA, Gansheroff LJ, Mills M, et al. Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infect Immun, 2002, 70(5): 2414-2418.
9Jenkins C, Chart H, Smith HR, et al. Antibody response of patients infected with verocytotoxin-producing Escherichia coli to protein antigens encoded on the LEE locus. J Med Microbiol, 2000, 49(1): 97-101.
10Gansheroff LJ, Wachtel MR, O′Brien AD. Decreased adherence of enterohemorrhagic Escherichia coli to HEp-2 cells in the presence of antibodies that recognize the C-terminal region of intimin. Infect Immun, 1999, 67(12): 6409-6417.
6Kotloff KL, Winickoff JP,Ivanoff B, et al. Global burden ofShigella infections : implications for vaccine development andimplementation of control strategies [J]. Bull World HealthOrgan, 1999, 77(8) :651-666.
7Levine MM, Kotloff KL, Barry EM, et al. Clinical trials ofShigella vaccines : two steps forward and one step back on a long,hard road [J]. Nat Rev Microbiol, 2007,5(7) :540-553.
8von Seidlein L, Kim DR, Ali M, et al. A multicentre study ofShigella diarrhoea in six Asian countries : disease burden,clinicalmanifestations,and microbiology [J]. PLoS Med,2006,3(9) :e353.
9Niyogi SK. Increasing antimicrobial resistance - an emergingproblem in the treatment of shigellosis [J]. Clin Microbiol Infect,2007,13(12):1141-1143.
10Formal SB, Oaks EV, Olsen RE, et al. Effect of prior infectionwith virulent Shigella flexneri 2a on the resistance of monkeys tosubsequent infection with Shigella sonnei [J]. J Infect Dis,1991, 164(3) :533-537.
